Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 436 clinical trials
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

measurable disease
follicular lymphoma grade iiib
18f-fdg
ebv-positive dlbcl, nos
immunodeficiency
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX (cetuximab) in adults with recurrent and/or metastatic solid tumors.

measurable disease
head and neck cancer
interleukin-2
gilbert's syndrome
cetuximab
  • 0 views
  • 19 Feb, 2024
  • 6 locations
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

metastatic melanoma
chronic lymphocytic leukemia
esophageal cancer
zanubrutinib
MRI
  • 0 views
  • 19 Feb, 2024
  • 4 locations
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS  

To study the safety and maximum tolerated dose (MTD) of combined chemotherapy when it is administered to patients with advanced Kaposi's sarcoma together with one of two different doses of zidovudine (AZT).The combination of AZT and chemotherapy may be effective in treating the tumor as well as preventing the life-threatening …

  • 0 views
  • 22 Apr, 2026
  • 1 location
Divyani - Group-Based Acceptance and Commitment Therapy Versus Active Control in University Students With Emotional Symptoms (ACT-EMA-RCT)  

This study evaluates the efficacy of a group-based Acceptance and Commitment Therapy (ACT) protocol compared to a non-directive group therapy used as an active control condition in university students presenting moderate to moderate/high levels of emotional symptomatology.Emotional difficulties such as depressive and anxiety symptoms are highly prevalent among university students …

  • 0 views
  • 02 Apr, 2026
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease  

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

alzheimer's disease
  • 0 views
  • 09 May, 2025
  • 3 locations
Nutritional Study of Fish Oil in Skin Quality in Healthy Women test 22222 (OPTIHUD)  

test sync --- The skin acts as a barrier against the external environment and prevents water loss from the body. Aging is a natural process leading to changes in the skin and fish oil has been shown to prevent inflammation, hyperpigmentation and UV-damage. This pilot study will determine skin characteristics …

Accepts healthy volunteers
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Effect of a Dietary Iron Program on Iron Status and IQ in Children in Phatthalung Province, Thailand123  

Iron deficiency (ID) continues to be one of the most prevalent disorders, which can adversely affect cognitive ability in childhood. Our aim was to determine the effect of a dietary iron education program (DIP) on children's iron status and intelligence quotient (IQ) score. This pre-test (week 1) post-test (week 16) …

Accepts healthy volunteers
  • 0 views
  • 23 Aug, 2024
  • 0 views
  • 25 Apr, 2024
  • 1 location
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy (VERDANT)  

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine …

  • 0 views
  • 17 Feb, 2025
  • 1 location